Trial shows Roche’s new flu drug helps reduce symptoms in at-risk patients
Pharmaphorum Media Limited | October 04, 2018
Baloxavir marboxil, a flu drug seen by Roche as a successor to Tamiflu, significantly sped time to relief for patients highly vulnerable to serious complications. The Swiss firm said that if the single dose oral drug is approved, it could be the first new method of treating flu for two decades. Roche is planning filings with regulators after the phase 3 CAPSTONE-2 trial showed baloxavir marboxil significantly reduced the time to the improvement of flu symptoms compared with placebo.